Diclofenac
Brand names: Voltarol, Diclomax
Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) used for pain and inflammation; in older people it requires particular caution because of cumulative cardiovascular, gastrointestinal and renal risks.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It inhibits cyclo-oxygenase (COX-1 and COX-2), reducing prostaglandin synthesis and thereby decreasing inflammation, pain and fever.
Prescribing in practice
- In older patients the cardiovascular, gastrointestinal bleeding and renal risks are amplified; diclofenac carries a relatively high cardiovascular risk and is generally avoided, with the lowest effective dose for the shortest time if used and gastroprotection considered.
- Avoid or use great caution with concurrent anticoagulants, antiplatelets, ACE inhibitors/ARBs, diuretics and other NSAIDs, and in heart failure, peptic ulcer disease or significant renal impairment.
- It is contraindicated in established ischaemic heart disease, cerebrovascular disease, peripheral arterial disease and heart failure.
Monitoring
Monitor renal function and blood pressure, and watch for gastrointestinal and cardiovascular symptoms, especially in dehydrated or polypharmacy patients.
Counselling the patient
- Take with or after food and report any black stools, vomiting blood or indigestion promptly.
- Do not combine with other anti-inflammatory painkillers, including over-the-counter ones.
- Use for the shortest time needed and report ankle swelling, breathlessness or reduced urine output.
Evidence & guidelines
MHRA advice and large cardiovascular safety reviews confirm diclofenac carries an elevated thrombotic risk comparable to some COX-2 inhibitors, supporting restricted use in older and at-risk patients.
Reference: MHRA Drug Safety Update 2013 (diclofenac cardiovascular risk); AGS Beers Criteria 2023; STOPP/START v3; NICE CG177; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Vancomycin Dosing Calculator · Drug Dosing
- Phenytoin Correction for Albumin / Renal Failure · Drug Dosing
- Local Anaesthetic Maximum Dose Calculator · Drug Dosing
- Tisdale Risk Score for QT Prolongation · Arrhythmia
- Bazett Corrected QT Interval (QTc) Calculator · Arrhythmia
- DAPT Score for Dual Antiplatelet Therapy Duration · Antiplatelet Therapy
- Falls Assessment in Older Adults · NICE CG161 2013
- Delirium Outside ICU · NICE CG103
- Comprehensive Geriatric Assessment (CGA) · BGS / NICE
- Delirium Assessment and Management · NICE CG103 2010
- Frailty Recognition and Management · BGS Frailty Framework / NHS NHSE
- Polypharmacy and Medicines Optimisation · STOPP/START v2 2014 / NICE NG5